GlaxoSmithKline

Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009

Data Include First Presentation of Phase III Progression Free Survival Results for Pazopanib in Kidney Cancer LONDON and PHILADELPHIA, May 11 /PRNewswire/ -- GlaxoSmithKline (GSK) Oncology announced that new clinical data from nine of its oncology molecules will be featured in various pre...

IADR and GlaxoSmithKline Consumer Healthcare announce winners of 2009 Innovation in Oral Care Awards

Alexandria, Va. The International Association for Dental Research (IADR) and GlaxoSmithKline (GSK) Consumer Healthcare today announced the 2009 winners of the annual IADR/GSK Innovation in Oral Care Awards. The three prestigious awards recognize research in innovative oral care technologies that ...

GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance : – Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases –

GlaxoSmithKline (LSE:GSK) (NYSE:GSK) and Dynavax Technologies Corporation (NASDAQ:DVAX) today announced a worldwide strategic alliance to discover, develop and commercialize novel inhibitors of endosomal Toll-like Receptors (TLRs) for the treatment of immuno-inflammatory diseases. TLRs are key re...

Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking

In response to the announcement by the Federal Aviation Administration (FAA), Commit Lozenges now offered to pilots and air traffic controllers who are quitting smoking PITTSBURGH, May 23 /PRNewswire/ -- With the Federal Aviation Administration's (FAA) recent announce...

IADR and GlaxoSmithKline Consumer Healthcare announce winners

Alexandria, Va. The International Association for Dental Research (IADR) and GlaxoSmithKline (GSK) Consumer Healthcare today announced the 2008 winners of the annual IADR/GSK Innovation in Oral Care Awards. The three prestigious awards recognize research in innovative oral care technologies that ...

A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence

PARSIPPANY, N.J., May 7 /PRNewswire/ -- GlaxoSmithKline (GSK) Consumer Healthcare, marketer of the leading smoking cessation products including Nicorette(R) gum, NicoDerm(R) CQ(R) patch, and Commit(R) lozenge, applauds the release of the updated 2008 U.S. Public Health Service (PHS) Guideline ...

EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties

Out-Licensing Enhances EUSA's Strategic Focus on Late-Stage and Marketed Products DOYLESTOWN, Pennsylvania and OXFORD, England, February 18 /PRNewswire/ -- EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain contro...

Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program

Deal follows positive phase I data from novel product candidate AM103 for the oral treatment of respiratory disease SAN DIEGO, Feb. 4 /PRNewswire/ -- Amira Pharmaceuticals and GlaxoSmithKline today announced they have entered into a worldwide exclusive agreement to develop, manufa...

Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds

Lead Selections Trigger Milestone Payments Totaling $1 Million to Pharmacopeia PRINCETON, N.J., Nov. 27 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP ), an innovator in the discovery and development of novel small molecule therapeutics, announced today t...

Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program

Summary: Genmab and GSK Have Announced the Initiation of the Phase III Program With Ofatumumab to Treat Rheumatoid Arthritis. COPENHAGEN, Denmark, November 20 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today the initiation of the ...

More>>

GlaxoSmithKline in Medical Technology

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

ROCKVILLE, Maryland and LONDON, July 20 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) met the primary endpoint in BLISS-52, the first of two pivotal P...

FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight

ROCKVILLE, Md. , June 8 /PRNewswire-FirstCall/ -- Attached is a press release issued yesterday by GlaxoSmithKline (GSK), regarding new Phase 2 data for Syncria(R) (albiglutide) presented at the American Diabetes Association 69th Scientific Sessions in New Orleans. (Logo: http://www.newsco...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

ORLANDO, Fla. , May 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline [NYSE: GSK] and Genmab A/S [OMX: GEN] today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to three that the ARZERRA(TM) (ofatumumab) data are reasonably like...

Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

OXFORD, England, May 18 /PRNewswire/ -- - New Alliance a Key Step for OBT to Broaden its Exciting Pipeline of Therapeutic Antibodies Oxford BioTherapeutics (OBT) today announced a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic an...

Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV

CAMBRIDGE, Mass. and LONDON, Feb. 6 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ) and GlaxoSmithKline (GSK) today announced the execution of a license agreement granting GSK exclusive worldwide rights to IDX899. IDX899 is a novel non-nucleoside reverse transcriptase inh...

Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study

Summary: Phase III Pivotal Study of Ofatumumab in Refractory CLL Meets Primary Endpoint COPENHAGEN, July 31 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today positive top-line results from an interim analysis of ...

Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline

CAMBRIDGE, England, January 12 /PRNewswire/ -- Biotica Technology Limited, a privately-held biotechnology company, announces a significant Collaboration and License Agreement with GlaxoSmithKline to discover, develop and commercialise novel erythromycin-based macrolides in inflammatory disease...

Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline

WELLESLEY, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. (Nasdaq: COLY ), today announced that the company has received a $3.0 million milestone payment from GlaxoSmithKline (GSK) associated with the initiation of GSK's Phase III clinical trial in non-small cell lu...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...mpanies also contributed to the increase in the Company's revenue: Regulus Therapeutics earned revenue from its strategic alliance with glaxosmithkline (GSK), including a $500,000 discovery milestone payment. Isis entered into a license agreement with Alnylam, which provided an $11 million li...

First Potential Lupus-Specific Treatment in Sight

..., July 20 /PRNewswire-USNewswire/ -- Today, Human Genome Sciences (HGS) and glaxosmithkline (GSK) announced positive results from a year-long clinical trial of BENLYST...hat lupus requires. "We are grateful to Human Genome Sciences and glaxosmithkline for their pioneering efforts to develop a new, safe, effective and tolerabl...

GlaxoSmithKline in Medical Dictionary

Depression

... glaxosmithkline site describing common forms of depression , the medications and therapies available to treat depressive disorders, and more. If you've been diag...

GlaxoSmithKline in Biological News

Another JDRF partner moves research forward with collaboration agreement for diabetes treatment

...diabetes to market faster. Other IDDP partners that have created similar agreements include: Tolerx, based in Massachusetts, which has joined with glaxosmithkline to develop an anti-CD3 antibody to preserve beta cell function in newly diagnosed patients; Maryland-based MacroGenics, which is developing a similar ...

CHIs 5th Biomarker World Congress: Signature Event with Cutting-Edge Agenda

...re Technologies Group, Discovery Technology Group, glaxosmithkline John C. Bloom, V.M.D., Ph.D., Executive Dir...Hariry, M.D., Ph.D., Group Director, Oncology MDC, glaxosmithkline Research & Development Robert E. Epstei..., Department of Biostatistics and Data Management, glaxosmithkline Francois Legay, Ph.D., Global Head, Marker ...

Lancet study supports new, highly effective treatment for blood disorder

...upported by GlaxoSmithKline. Dr. Bussel is a paid advisory board member for glaxosmithkline and has received research grant support, lecture fees, and consulting fees from glaxosmithkline and reports equity ownership in GlaxoSmithKline. Immune thrombocytopenic...

International public-private partnership offers new paradigm for medicinal chemistry

... tradition of keeping such data confidential. The public-private partnership, to be led by the Structural Genomics Consortium (SGC), also involves glaxosmithkline (GSK), the National Institutes of Health Chemical Genomics Center (NCGC) in Bethesda, USA, and the Departments of Chemistry and Biochemistry at the Un...

Researchers discover baldness gene: 1 in 7 men at risk

... This release is also available in French . Researchers at McGill University, King's College London and glaxosmithkline Inc. have identified two genetic variants in caucasians that together produce an astounding sevenfold increase the risk of male pattern baldness. Thei...

American Society for Microbiology honors Victor de Lorenzo

... Washington, DCMay 28, 2008The 2008 American Society for Microbiology (ASM) glaxosmithkline International Member of the Year Award is presented to Vctor de Lorenzo, Pr...Ph.D. in Biochemistry from the Universidad Autnoma de Madrid, Spain. The glaxosmithkline International Member of the Year Award is presented during the 108th Genera...

Long-term study of middle-aged mice shows

... CAMBRIDGE, Mass., July 3, 2008 -- Sirtris, a glaxosmithkline company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, is included among a research te...

Tamoxifen-like drug suggests new ways to selectively block estrogen

...specific effects. In the May 13, 2005, issue of Molecular Cell, researchers from the University of Chicago, Renz Research, Inc., Duke University and glaxosmithkline show how GW5638 fits into a pocket in the estrogen receptor in a way that differs slightly, but importantly, from how tamoxifen fits. The slight diffe...

South African Tribunal Asks For Damages Estimates in GSK AIDS Drug Case

... A landmark South African legal complaint against British drug maker glaxosmithkline (GSK) over its AIDS drug pricing and policies in that country will proceed following an order late last week by South Africa's Competition Tribunal th...

GlaxoSmithKline in Biological Technology

Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)

THOUSAND OAKS, Calif. and LONDON, July 27 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosi...

Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD

PHILADELPHIA, March 31 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company, today announced a co-promotion agreement with GlaxoSmithKline plc (NYSE: GSK ) for VYVANSE(R) (lisdexamfetamine dimesylate) capsules CII with the aim of im...

Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes

ROCKVILLE, Md., Feb. 17 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced that GlaxoSmithKline (NYSE: GSK ) has initiated a Phase 3 clinical trial program to evaluate the efficacy, safety and tolerability of Syncria (R) (albiglutide) in the long-term treatm...

BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization

PRINCETON, N.J., Dec. 8 /PRNewswire/ -- BioWa, Inc., announced today that it licensed to GlaxoSmithKline (NYSE: GSK ) its POTELLIGENT(R) Technology for use in developing and commercializing select GSK antibodies with enhancement of antibody-dependent cellular cytotoxicity (ADCC). "GSK is...

Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration

Exelixis Generated 10 IND Compounds and Received over $235 Million SOUTH SAN FRANCISCO, Calif., June 27 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) announced today that the company and GlaxoSmithKline, Inc. (NYSE: GSK ) will bring their six-year collaboration to a successful ...

BioWa Announces Licensing of BioWa's POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development

PRINCETON, N.J., Oct. 19 /PRNewswire/ -- BioWa, Inc. (BioWa) announced today that it has entered into a research agreement which provides GlaxoSmithkline (GSK) with access to BioWa's patented POTELLIGENT(R) Technology platform for the development of antibody-dependent cellular cytotoxicity (AD...

CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline

ATLANTA and PHILADELPHIA, June 26 /PRNewswire-FirstCall/ -- Highlights Include: -- GSK's ROTARIX(R) [Rotavirus Vaccine, Live, Oral] recommended for routine vaccination of infants to protect against rotavirus gastroenteritis (RGE) -- ROTARIX, approved by the FDA on April 3, 2008, is the o...

Pharmacopeia to Receive $5 Million Payment from GlaxoSmithKline

Payment Triggered by Pharmacopeia's Achievement of Collaboration Criteria PRINCETON, N.J., March 18 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP ), an innovator in the discovery and development of novel small molecule therapeutics, announced today that it will receive a payment of $5 m...

Ingenuity Systems Extends Enterprise-Level Software Agreement With GlaxoSmithKline

REDWOOD CITY, Calif., March 18 /PRNewswire/ -- Ingenuity Systems, the leading provider of information solutions for life science researchers, has announced that they have extended and expanded their existing license agreement with GlaxoSmithKline for access to Ingenuity Pathways Analysis (IPA)...

Vaccinex Antibody Licensed to GlaxoSmithKline

ROCHESTER, N.Y., Feb. 15 /PRNewswire/ -- EUSA Pharma (Oxford, UK), a Vaccinex collaboration partner, has announced that it has licensed OP-R003, a human anti-interleukin-6 antibody discovered by Vaccinex, to GlaxoSmithKline. According to the terms of the product license, GSK will pay an up-f...

GlaxoSmithKline in Biological Definition

Malaria

...elopment, with no completely effective vaccine yet available (as of November 2004 ). A team backed by the Gates Foundation and the pharma giant glaxosmithkline announced a partially successful field trial in October 2004 , for RTS,S/AS02A , a vaccine which reduces infection risk by 30% and severity of inf...